RP104 is a proprietary delayed-release tablet formulation of cysteamine bitartrate, used as a treatment option for non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD)
The results demonstrated that GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrotic cells were present. The study also suggests
The DataLabs EDC solution is believed to simplify workflows and streamline the process from study design to data collection, management, and reporting. The solution is offered as a
The transaction covers Dermik assets comprising an aesthetic and therapeutic business in the US and Canada, as well as an aesthetic business worldwide. Sanofi’s Laval, Canada site, which
PureTrim Truffles, which is chocolate flavored, is believed to help people to stay on track during their weight loss routines. The product made from organic ingredients is free
Vernalis is entitled to receive a payment of £0.4m from Lundbeck and the collaboration will now advance into its third stage. Vernalis will receive fees and a potential
The funding comprises $750,000 from the Muscular Dystrophy Association (MDA), $250,000 from Parent Project Muscular Dystrophy (PPMD) and $500,000 from a group of four independent Duchenne foundations spanning
The Phase I study of GLPG0778 is a part of an immuno-inflammatory alliance with GSK, and involved 45 healthy volunteers, who were divided into 5 cohorts, receiving in
The company intends to manufacture total of 480 million doses of the vaccine, which is in line with its commitment made in March 2010 to supply up to
The production of SSC is said to make use of the company’s proprietary biotechnology which will reduce energy consumption by 66%, produce 90% less waste and have 50%
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.